查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1797060

荷爾蒙避孕藥市場－全球產業規模、佔有率、趨勢、機會和預測（按方法、荷爾蒙、地區和競爭細分，2020-2030 年）

Hormonal Contraceptives Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Method, By Hormone, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年，全球荷爾蒙避孕藥市場規模達172.5億美元，預計到2030年將達255.7億美元，預測期內複合年成長率為6.78%。全球荷爾蒙避孕藥市場正在經歷顯著成長，這得益於人們對口服避孕藥使用及其在預防意外懷孕和控制人口方面的益處的認知不斷提高，這顯著增加了全球各地對荷爾蒙避孕藥的需求。此外，隨著荷爾蒙避孕藥的使用率顯著提高，以及不同年齡層女性對安全生活方式意識的不斷增強，預計未來對不同荷爾蒙避孕方法的需求將進一步增加，從而推動市場成長。例如，2021 年 4 月，美國食品藥物管理局批准了 Mayne Pharma 銷售的屈螺酮和雌四醇複方片劑 Nextstellis，用於避孕，這是首批含有天然雌激素的複方藥之一。

市場概覽
預測期 2026-2030
2024年市場規模 172.5億美元
2030年市場規模 255.7億美元
2025-2030 年複合年成長率 6.78%
成長最快的領域 僅含黃體素
最大的市場 北美洲

關鍵市場促進因素

政府大力推行計劃生育和生殖健康舉措

主要市場挑戰

荷爾蒙避孕藥的健康風險和副作用

主要市場趨勢

長效可逆避孕藥（LARC）日益受到青睞

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：臨床試驗分析

第6章：全球荷爾蒙避孕藥市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依方法（避孕藥、子宮內避孕器、注射、陰道環、植入物、其他）
    • 依激素（組合荷爾蒙避孕藥和僅含黃體素的避孕藥）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 依方法
    • 按激素
    • 按地區

第7章：北美荷爾蒙避孕藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第8章：歐洲荷爾蒙避孕藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章：亞太地區荷爾蒙避孕藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第10章：南美洲荷爾蒙避孕藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲荷爾蒙避孕藥市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 12 章：市場動態

  • 驅動程式
  • 挑戰

第13章：市場趨勢與發展

  • 最新動態
  • 併購
  • 產品發布

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品/服務的威脅

第 15 章：SWOT 分析：全球荷爾蒙避孕藥市場

第 16 章：競爭格局

  • Abbvie, Inc.
  • Afaxys, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Bayer AG
  • Merck KGaA
  • Organon Group of Companies
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Pregna International Ltd.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 14350

Global Hormonal Contraceptives Market was valued at USD 17.25 Billion in 2024 and is expected to reach USD 25.57 Billion by 2030 with a CAGR of 6.78% during the forecast period. The global market for Hormonal Contraceptives is experiencing significant growth, driven by the growing awareness regarding usage of oral contraceptive and its benefits for preventing the unintended pregnancy and population control significantly increased the demand for hormonal contraceptives across different parts of the globe. Additionally, ahavetion of hormonal contraceptives has significantly increased and increasing awareness among women of different age group for leading the safe life is further expected to increase the demand for different hormonal contraceptives procedures, thereby fuelling the market growth. For instance, in April 2021, the Food and Drug Administration approved a combination of drospirenone and estetrol tablet Nextstellis marketed by Mayne Pharma for preventing pregnancy, one of the first combination pills containing naturally occurring estrogen.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 17.25 Billion
Market Size 2030USD 25.57 Billion
CAGR 2025-20306.78%
Fastest Growing SegmentProgestin Only
Largest MarketNorth America

Key Market Drivers

Rising Government Initiatives to Promote Family Planning and Reproductive Health

One of the primary drivers of growth in the global hormonal contraceptives market is the significant investment by governments and international health organizations in reproductive health and family planning programs. Hormonal contraceptives-including oral pills, patches, injections, implants, and vaginal rings-form the cornerstone of modern contraception. Their widespread availability and integration into public health systems are largely supported by government policies that aim to reduce unintended pregnancies, maternal mortality, and child morbidity. The World Health Organization (WHO) states that around 257 million women globally who want to avoid pregnancy are not using safe or modern contraceptive methods. To address this unmet need, numerous governments have scaled up access to hormonal contraceptives through national programs. For instance, the U.S. federal Title X Family Planning Program supports clinics in offering affordable or free birth control to low-income individuals. According to the Office of Population Affairs (OPA), Title X clinics served 1.5 million individuals in 2022 alone, and over 99% of those clients received contraceptive services.

In developing countries, such as India, the Ministry of Health and Family Welfare operates the National Family Planning Program, which provides subsidized contraceptives through public health centers. As of 2023, the Indian government distributed over 20 million cycles of oral contraceptive pills under its Mission Parivar Vikas scheme. These expansive efforts ensure continuous market demand for hormonal contraceptives and stimulate innovation and supply chain efficiency. In effect, public health policies aimed at increasing contraceptive prevalence are driving hormonal contraceptive market growth across regions.

Key Market Challenges

Health Risks and Side Effects Associated with Hormonal Contraceptives

Despite their widespread use and effectiveness, hormonal contraceptives are associated with various health risks and side effects, which pose a significant challenge to market growth. Hormonal contraceptives function by altering a woman's hormone levels to prevent ovulation, and this hormonal interference can lead to adverse effects such as mood swings, weight gain, nausea, headaches, and menstrual irregularities. More serious risks include an increased likelihood of blood clots, cardiovascular complications, and, in rare cases, certain types of cancer. A study by the National Cancer Institute (NCI) reported a slight increase in the risk of breast and cervical cancer among long-term users of hormonal contraceptives, although they may reduce the risk of ovarian and endometrial cancers.

In 2019, the U.S. Food and Drug Administration (FDA) updated warnings on combined hormonal contraceptives (CHCs) about the risk of venous thromboembolism (VTE), especially for products containing drospirenone. Similarly, regulatory agencies in Europe, such as the European Medicines Agency (EMA), have recommended stronger warnings and educational efforts to ensure informed use. Concerns about side effects can lead to discontinuation or switching to non-hormonal methods, particularly in high-risk populations such as smokers over 35, obese individuals, and those with hypertension or a family history of thrombotic disorders. These health considerations reduce user confidence and affect market penetration, especially among new adopters. As awareness of potential adverse effects grows, particularly through social media and health advocacy platforms, it may hinder widespread adoption unless offset by education, personalized medical guidance, and the development of safer formulations.

Key Market Trends

Increasing Preference for Long-Acting Reversible Contraceptives (LARCs)

A prominent trend reshaping the hormonal contraceptives landscape is the growing preference for Long-Acting Reversible Contraceptives (LARCs) such as hormonal intrauterine devices (IUDs) and subdermal implants. These methods offer extended protection ranging from three to ten years, minimal maintenance, and high efficacy-qualities that are increasingly appealing to women globally, particularly those seeking convenience and long-term reproductive autonomy. According to the U.S. Centers for Disease Control and Prevention (CDC), LARCs have the lowest failure rates among contraceptive methods-less than 1%-compared to 7% for oral contraceptive pills. This reliability, combined with a low requirement for user adherence, has fueled rapid adoption, especially in developed countries with well-established healthcare systems.

Government programs are also promoting LARCs as part of comprehensive reproductive healthcare. For instance, the UK's National Health Service (NHS) includes hormonal IUDs in its publicly funded contraceptive offerings. In the U.S., state-level Medicaid expansion has been linked to increased access and uptake of LARCs, particularly in underserved populations. A report from the Kaiser Family Foundation found that the use of LARCs among U.S. women aged 15-44 increased from 8.5% in 2009 to 14% in 2020. In low- and middle-income countries, international bodies like UNFPA and USAID have rolled out LARC-focused initiatives to reduce unmet contraceptive needs. These global efforts, combined with innovations in hormonal implant technologies, are likely to sustain the rising demand for LARCs over the coming decade.

Key Market Players

  • Abbvie, Inc.
  • Afaxys, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Bayer AG
  • Merck KGaA
  • Organon Group of Companies
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Pregna International Ltd.

Report Scope:

In this report, the Global Hormonal Contraceptives Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hormonal Contraceptives Market, By Method:

  • Pill
  • Intrauterine Device
  • Injectable
  • Vaginal Ring
  • Implant
  • Others

Hormonal Contraceptives Market, By Hormone:

  • Combination Hormonal Contraceptives
  • Progestin Only

Hormonal Contraceptives Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Hormonal Contraceptives Market.

Available Customizations:

Global Hormonal Contraceptives Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Hormonal Contraceptives Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Method (Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, Others)
    • 6.2.2. By Hormone (Combination Hormonal Contraceptives v/s Progestin Only)
    • 6.2.3. By Region
    • 6.2.4. By Company (2024)
  • 6.3. Market Map
    • 6.3.1. By Method
    • 6.3.2. By Hormone
    • 6.3.3. By Region

7. North America Hormonal Contraceptives Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Method
    • 7.2.2. By Hormone
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Hormonal Contraceptives Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Method
        • 7.3.1.2.2. By Hormone
    • 7.3.2. Canada Hormonal Contraceptives Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Method
        • 7.3.2.2.2. By Hormone
    • 7.3.3. Mexico Hormonal Contraceptives Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Method
        • 7.3.3.2.2. By Hormone

8. Europe Hormonal Contraceptives Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Method
    • 8.2.2. By Hormone
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Hormonal Contraceptives Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Method
        • 8.3.1.2.2. By Hormone
    • 8.3.2. Germany Hormonal Contraceptives Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Method
        • 8.3.2.2.2. By Hormone
    • 8.3.3. United Kingdom Hormonal Contraceptives Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Method
        • 8.3.3.2.2. By Hormone
    • 8.3.4. Italy Hormonal Contraceptives Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Method
        • 8.3.4.2.2. By Hormone
    • 8.3.5. Spain Hormonal Contraceptives Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Method
        • 8.3.5.2.2. By Hormone

9. Asia-Pacific Hormonal Contraceptives Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Method
    • 9.2.2. By Hormone
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Hormonal Contraceptives Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Method
        • 9.3.1.2.2. By Hormone
    • 9.3.2. India Hormonal Contraceptives Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Method
        • 9.3.2.2.2. By Hormone
    • 9.3.3. Japan Hormonal Contraceptives Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Method
        • 9.3.3.2.2. By Hormone
    • 9.3.4. South Korea Hormonal Contraceptives Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Method
        • 9.3.4.2.2. By Hormone
    • 9.3.5. Australia Hormonal Contraceptives Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Method
        • 9.3.5.2.2. By Hormone

10. South America Hormonal Contraceptives Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Method
    • 10.2.2. By Hormone
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Hormonal Contraceptives Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Method
        • 10.3.1.2.2. By Hormone
    • 10.3.2. Argentina Hormonal Contraceptives Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Method
        • 10.3.2.2.2. By Hormone
    • 10.3.3. Colombia Hormonal Contraceptives Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Method
        • 10.3.3.2.2. By Hormone

11. Middle East and Africa Hormonal Contraceptives Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Method
    • 11.2.2. By Hormone
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Hormonal Contraceptives Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Method
        • 11.3.1.2.2. By Hormone
    • 11.3.2. Saudi Arabia Hormonal Contraceptives Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Method
        • 11.3.2.2.2. By Hormone
    • 11.3.3. UAE Hormonal Contraceptives Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Method
        • 11.3.3.2.2. By Hormone

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products/Services

15. SWOT Analysis: Global Hormonal Contraceptives Market

16. Competitive Landscape

  • 16.1. Abbvie, Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Afaxys, Inc.
  • 16.3. Teva Pharmaceuticals Industries Ltd.
  • 16.4. Bayer AG
  • 16.5. Merck KGaA
  • 16.6. Organon Group of Companies
  • 16.7. Pfizer Inc.
  • 16.8. Johnson & Johnson Services, Inc.
  • 16.9. Lupin Pharmaceuticals, Inc.
  • 16.10. Pregna International Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer